Home » Healthcare » Pharmaceuticals » Alpha Thalassemia Treatment Market

Alpha Thalassemia Treatment Market By Type Of Drugs (Folic Acid, Deferasirox, Deferiprone, Hydroxyurea) – Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Summary
Table Of Content

Market Insights

The alpha thalassemia treatment market was worth US$ 526.1 million in 2018 and is expected to grow at a 7.1% CAGR from 2019 to 2027. Alpha thalassemia is a congenital autosomal recessive disorder caused by an absence or reduction in alpha-globin peptides due to a deletion or mutation of the alpha-globin genes. Alpha thalassemia is usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region.

The key factors responsible for the growth of the alpha thalassemia treatment market are the rising awareness associated with thalassemia among medical practitioners and the public and the support provided by the government and non-government organizations to manage and treat thalassemia.

Market Synopsis

As the only approved drug for the treatment of alpha thalassemia, deferasirox will dominate the market throughout the forecast period.

Deferasirox will dominate the market in 2018, as it is the only drug therapy approved by the US Food and Drug Administration for alpha thalassemia. According to market experts, deferasirox has efficient oral bioavailability and a long half-life appropriate for once-daily dosing.

Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent manner. It is used widely across the world for alpha-thalassemia treatment because of its once-per-day oral dosage.

However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon, but there are a few drawbacks observed in phase IIa that might have some effect on its approval. If it gets approved, it will be observed as the fastest-growing drug in this market.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Increasing awareness related to the treatment and management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period.

The Asia Pacific will grow gradually throughout the forecast period from 2018 to 2026. The key factors responsible for the growth of the alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment and management and increasing support provided by governmental and non-governmental organizations to develop public awareness.

According to market experts, alpha-thalassemia is specifically common among Southeast Asian populations of Asian descent. 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.

Periods of History and Forecast

The alpha thalassemia treatment market was analyzed considering current market trends for the base year of 2018,and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report provides a detailed research study related to the alpha thalassemia treatment market, covering market interpretations and assumptions based on brief qualitative and quantitative data research carried out through primary and secondary research. Industry experts contributed to the analysis of market dynamics, such as drivers, opportunities, and challenges, which were further segmented by region and country.

This report also comprises a comprehensive analysis of the global alpha thalassemia treatment market, segmented by type of drug and geography. The report also gives data related to the competitive landscape of the major companies present and operating in the alpha thalassemia treatment market that covers detailed information, including company information such as the latest business strategies, financial data, and product profiles.

The key companies present in the market were analyzed and presented based on their product portfolios, current market updates, financial information, and key strategies. This report also covers attractive investment propositions evaluated with the help of PESTEL analysis, which is based on detailed geographical research. Major companies studied in the overall report are GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co., and Gilead Sciences, Inc., among others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

Which is the trending drug type in the market preferred for alpha thalassemia treatment, and why?
What are key companies’ current market strategies and policies, as well as the competitive landscape of the alpha thalassemia treatment market?
Which are the important and potential geographical markets (regions and countries) in the alpha thalassemia treatment market?
Which is the largest and fastest-growing region globally?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global ATT Market Portraiture
2.2. Global ATT Market, by Type of Drug, 2018 (US$ Mn)
2.3. Global ATT Market, by Geography, 2018 Vs 2027 (Value %)

Chapter 3. Global Alpha Thalassemia Treatment (ATT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Alpha Thalassemia Treatment (ATT) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Folic Acid
4.3. Deferasirox
4.4. Deferiprone
4.5. Hydroxyurea

Chapter 5. Global Alpha Thalassemia Treatment (ATT) Market, Pipeline Analysis
5.1. Overview
5.2. Darbepoetin Alfa (Phase III)
5.3. Enriched Hematopoetic Stem Cell Infusion (Phase II)
5.4. In utero hematopoietic stem cell transplantation (Phase I)

Chapter 6. Global Alpha Thalassemia Treatment (ATT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America ATT Market Analysis, 2017 – 2027
6.2.1. North America ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.2.2. North America ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe ATT Market Analysis, 2017 – 2027
6.3.1. Europe ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.3.2. Europe ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific ATT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America ATT Market Analysis, 2017 – 2027
6.5.1. Latin America ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.5.2. Latin America ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) ATT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.6.2. MEA ATT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. GlaxoSmithKline Plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Bellicum Pharmaceuticals
7.3. Novartis AG
7.4. Acceleron Pharma
7.5. Johnson & Johnson
7.6. Merck & Co Inc.
7.7. Alnylam Pharmaceuticals Inc.
7.8. Calimmune Inc.
7.9. Editas Medicine Inc.
7.10. Gilead Sciences Inc.

List of Figures

FIG. 1 Alpha Thalassemia Treatment (ATT): Market Segmentation
FIG. 2 Global ATT Market Share, by Type of Drugs, 2018 (US$ Mn)
FIG. 3 Global ATT Market, by Geography, 2018 Vs 2027 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2018
FIG. 5 Market Competition Landscape, by Key Players, 2018
FIG. 6 Global Folic Acid Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 7 Global Deferasirox Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Deferiprone Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Hydroxyurea Market for ATT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Darbepoetin Alfa Market for ATT, Till 2027 (US$ Mn)
FIG. 11 U.S. ATT Market, 2017 – 2027 (US$ Mn)
FIG. 12 Canada ATT Market, 2017 – 2027 (US$ Mn)
FIG. 13 U.K. ATT Market, 2017 – 2027 (US$ Mn)
FIG. 14 Germany ATT Market, 2017 – 2027 (US$ Mn)
FIG. 15 Rest Of Europe ATT Market, 2017 – 2027 (US$ Mn)
FIG. 16 Japan ATT Market, 2017 – 2027 (US$ Mn)
FIG. 17 China ATT Market, 2017 – 2027 (US$ Mn)
FIG. 18 Rest Of Asia Pacific ATT Market, 2017 – 2027 (US$ Mn)
FIG. 19 Brazil ATT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Mexico ATT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest Of Latin America ATT Market, 2017 – 2027 (US$ Mn)
FIG. 22 GCC ATT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Rest Of Middle East And Africa ATT Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Alpha Thalassemia Treatment (ATT) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 2 North America ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 3 North America ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 4 Europe ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 5 Europe ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Asia Pacific ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 7 Asia Pacific ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Latin America ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 9 Latin America ATT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Middle East & Africa ATT Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 11 Middle East And Africa ATT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 12 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Bellicum Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Acceleron Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Merck & Co Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Alnylam Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Calimmune Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Editas Medicine Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Gilead Sciences Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Alpha Thalassemia Treatment Market?

The market for Alpha Thalassemia Treatment Market is expected to reach USD$ 526.1 Mn in 2027.

What is the Alpha Thalassemia Treatment Market CAGR?

The Alpha Thalassemia Treatment Market is expected to see significant CAGR growth over the coming years, at 7.1%.

What is the Forecast period considered for Alpha Thalassemia Treatment Market?

The report is forecasted from 2019 -2027.

What is the base year considered for Alpha Thalassemia Treatment Market?

The base year of this report is 2018.

Who are the major players in this market?

GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –